News
Public · Published
AbbVie Earnings: Can Skyrizi and Rinvoq Replace Humira?
AbbVie's earnings now depend on the growth of its drugs Skyrizi and Rinvoq because sales of Humira are falling after U.S. biosimilar competitors entered the market.
Published:
Updated:
What happened
AbbVie’s earnings now depend on the growth of its drugs Skyrizi and Rinvoq because sales of Humira are falling after U.S. biosimilar competitors entered the market.
Confirmed
Global impact / market context
Humira has been AbbVie’s biggest revenue source, so its decline threatens overall earnings; strong performance of Skyrizi and Rinvoq could offset the loss and keep the company financially stable.
Analyst inference
U.S. biosimilars—lower‑cost copies of biologic drugs—are now approved for Humira, creating price pressure and reducing market share for the original product across the biotech sector.
Analyst inference
What to watch
- Quarterly sales growth of Skyrizi and Rinvoq, which will show if they can fill Humira’s revenue gap. Analyst inference
- Market share erosion of Humira as biosimilars gain prescriptions, indicating the speed of revenue loss. Analyst inference
- Any new regulatory approvals or label expansions for Skyrizi or Rinvoq that could boost their usage. Analyst inference